[<sup>89</sup>Zr]-Pertuzumab PET Imaging Reveals Paclitaxel Treatment Efficacy Is Positively Correlated with HER2 Expression in Human Breast Cancer Xenograft Mouse Models
Paclitaxel (PTX) treatment efficacy varies in breast cancer, yet the underlying mechanism for variable response remains unclear. This study evaluates whether human epidermal growth factor receptor 2 (HER2) expression level utilizing advanced molecular positron emission tomography (PET) imaging is co...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-03-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/26/6/1568 |
| _version_ | 1797541546443145216 |
|---|---|
| author | Yun Lu Meng Li Adriana V. F. Massicano Patrick N. Song Ameer Mansur Katherine A. Heinzman Benjamin M. Larimer Suzanne E. Lapi Anna G. Sorace |
| author_facet | Yun Lu Meng Li Adriana V. F. Massicano Patrick N. Song Ameer Mansur Katherine A. Heinzman Benjamin M. Larimer Suzanne E. Lapi Anna G. Sorace |
| author_sort | Yun Lu |
| collection | DOAJ |
| description | Paclitaxel (PTX) treatment efficacy varies in breast cancer, yet the underlying mechanism for variable response remains unclear. This study evaluates whether human epidermal growth factor receptor 2 (HER2) expression level utilizing advanced molecular positron emission tomography (PET) imaging is correlated with PTX treatment efficacy in preclinical mouse models of HER2+ breast cancer. HER2 positive (BT474, MDA-MB-361), or HER2 negative (MDA-MB-231) breast cancer cells were subcutaneously injected into athymic nude mice and PTX (15 mg/kg) was administrated. In vivo HER2 expression was quantified through [<sup>89</sup>Zr]-pertuzumab PET/CT imaging. PTX treatment response was quantified by [<sup>18</sup>F]-fluorodeoxyglucose ([<sup>18</sup>F]-FDG) PET/CT imaging. Spearman’s correlation, Kendall’s tau, Kolmogorov–Smirnov test, and ANOVA were used for statistical analysis. [<sup>89</sup>Zr]-pertuzumab mean standard uptake values (SUV<sub>mean</sub>) of BT474 tumors were 4.9 ± 1.5, MDA-MB-361 tumors were 1.4 ± 0.2, and MDA-MB-231 (HER2−) tumors were 1.1 ± 0.4. [<sup>18</sup>F]-FDG SUV<sub>mean</sub> changes were negatively correlated with [<sup>89</sup>Zr]-pertuzumab SUV<sub>mean</sub> (r = −0.5887, <i>p</i> = 0.0030). The baseline [<sup>18</sup>F]-FDG SUV<sub>mean</sub> was negatively correlated with initial [<sup>89</sup>Zr]-pertuzumab SUV<sub>mean</sub> (r = −0.6852, <i>p</i> = 0.0002). This study shows PTX treatment efficacy is positively correlated with HER2 expression level in human breast cancer mouse models. Molecular imaging provides a non-invasive approach to quantify biological interactions, which will help in identifying chemotherapy responders and potentially enhance clinical decision-making. |
| first_indexed | 2024-03-10T13:17:29Z |
| format | Article |
| id | doaj.art-8486229e4f754d789d946344429c7cbc |
| institution | Directory Open Access Journal |
| issn | 1420-3049 |
| language | English |
| last_indexed | 2024-03-10T13:17:29Z |
| publishDate | 2021-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj.art-8486229e4f754d789d946344429c7cbc2023-11-21T10:17:59ZengMDPI AGMolecules1420-30492021-03-01266156810.3390/molecules26061568[<sup>89</sup>Zr]-Pertuzumab PET Imaging Reveals Paclitaxel Treatment Efficacy Is Positively Correlated with HER2 Expression in Human Breast Cancer Xenograft Mouse ModelsYun Lu0Meng Li1Adriana V. F. Massicano2Patrick N. Song3Ameer Mansur4Katherine A. Heinzman5Benjamin M. Larimer6Suzanne E. Lapi7Anna G. Sorace8Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35233, USADepartment of Radiology, University of Alabama at Birmingham, Birmingham, AL 35233, USADepartment of Radiology, University of Alabama at Birmingham, Birmingham, AL 35233, USADepartment of Radiology, University of Alabama at Birmingham, Birmingham, AL 35233, USADepartment of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL 35233, USADepartment of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL 35233, USADepartment of Radiology, University of Alabama at Birmingham, Birmingham, AL 35233, USADepartment of Radiology, University of Alabama at Birmingham, Birmingham, AL 35233, USADepartment of Radiology, University of Alabama at Birmingham, Birmingham, AL 35233, USAPaclitaxel (PTX) treatment efficacy varies in breast cancer, yet the underlying mechanism for variable response remains unclear. This study evaluates whether human epidermal growth factor receptor 2 (HER2) expression level utilizing advanced molecular positron emission tomography (PET) imaging is correlated with PTX treatment efficacy in preclinical mouse models of HER2+ breast cancer. HER2 positive (BT474, MDA-MB-361), or HER2 negative (MDA-MB-231) breast cancer cells were subcutaneously injected into athymic nude mice and PTX (15 mg/kg) was administrated. In vivo HER2 expression was quantified through [<sup>89</sup>Zr]-pertuzumab PET/CT imaging. PTX treatment response was quantified by [<sup>18</sup>F]-fluorodeoxyglucose ([<sup>18</sup>F]-FDG) PET/CT imaging. Spearman’s correlation, Kendall’s tau, Kolmogorov–Smirnov test, and ANOVA were used for statistical analysis. [<sup>89</sup>Zr]-pertuzumab mean standard uptake values (SUV<sub>mean</sub>) of BT474 tumors were 4.9 ± 1.5, MDA-MB-361 tumors were 1.4 ± 0.2, and MDA-MB-231 (HER2−) tumors were 1.1 ± 0.4. [<sup>18</sup>F]-FDG SUV<sub>mean</sub> changes were negatively correlated with [<sup>89</sup>Zr]-pertuzumab SUV<sub>mean</sub> (r = −0.5887, <i>p</i> = 0.0030). The baseline [<sup>18</sup>F]-FDG SUV<sub>mean</sub> was negatively correlated with initial [<sup>89</sup>Zr]-pertuzumab SUV<sub>mean</sub> (r = −0.6852, <i>p</i> = 0.0002). This study shows PTX treatment efficacy is positively correlated with HER2 expression level in human breast cancer mouse models. Molecular imaging provides a non-invasive approach to quantify biological interactions, which will help in identifying chemotherapy responders and potentially enhance clinical decision-making.https://www.mdpi.com/1420-3049/26/6/1568positron emission tomographyFDG-PETheterogeneityHER2+ breast cancermolecular imaging |
| spellingShingle | Yun Lu Meng Li Adriana V. F. Massicano Patrick N. Song Ameer Mansur Katherine A. Heinzman Benjamin M. Larimer Suzanne E. Lapi Anna G. Sorace [<sup>89</sup>Zr]-Pertuzumab PET Imaging Reveals Paclitaxel Treatment Efficacy Is Positively Correlated with HER2 Expression in Human Breast Cancer Xenograft Mouse Models Molecules positron emission tomography FDG-PET heterogeneity HER2+ breast cancer molecular imaging |
| title | [<sup>89</sup>Zr]-Pertuzumab PET Imaging Reveals Paclitaxel Treatment Efficacy Is Positively Correlated with HER2 Expression in Human Breast Cancer Xenograft Mouse Models |
| title_full | [<sup>89</sup>Zr]-Pertuzumab PET Imaging Reveals Paclitaxel Treatment Efficacy Is Positively Correlated with HER2 Expression in Human Breast Cancer Xenograft Mouse Models |
| title_fullStr | [<sup>89</sup>Zr]-Pertuzumab PET Imaging Reveals Paclitaxel Treatment Efficacy Is Positively Correlated with HER2 Expression in Human Breast Cancer Xenograft Mouse Models |
| title_full_unstemmed | [<sup>89</sup>Zr]-Pertuzumab PET Imaging Reveals Paclitaxel Treatment Efficacy Is Positively Correlated with HER2 Expression in Human Breast Cancer Xenograft Mouse Models |
| title_short | [<sup>89</sup>Zr]-Pertuzumab PET Imaging Reveals Paclitaxel Treatment Efficacy Is Positively Correlated with HER2 Expression in Human Breast Cancer Xenograft Mouse Models |
| title_sort | sup 89 sup zr pertuzumab pet imaging reveals paclitaxel treatment efficacy is positively correlated with her2 expression in human breast cancer xenograft mouse models |
| topic | positron emission tomography FDG-PET heterogeneity HER2+ breast cancer molecular imaging |
| url | https://www.mdpi.com/1420-3049/26/6/1568 |
| work_keys_str_mv | AT yunlu sup89supzrpertuzumabpetimagingrevealspaclitaxeltreatmentefficacyispositivelycorrelatedwithher2expressioninhumanbreastcancerxenograftmousemodels AT mengli sup89supzrpertuzumabpetimagingrevealspaclitaxeltreatmentefficacyispositivelycorrelatedwithher2expressioninhumanbreastcancerxenograftmousemodels AT adrianavfmassicano sup89supzrpertuzumabpetimagingrevealspaclitaxeltreatmentefficacyispositivelycorrelatedwithher2expressioninhumanbreastcancerxenograftmousemodels AT patricknsong sup89supzrpertuzumabpetimagingrevealspaclitaxeltreatmentefficacyispositivelycorrelatedwithher2expressioninhumanbreastcancerxenograftmousemodels AT ameermansur sup89supzrpertuzumabpetimagingrevealspaclitaxeltreatmentefficacyispositivelycorrelatedwithher2expressioninhumanbreastcancerxenograftmousemodels AT katherineaheinzman sup89supzrpertuzumabpetimagingrevealspaclitaxeltreatmentefficacyispositivelycorrelatedwithher2expressioninhumanbreastcancerxenograftmousemodels AT benjaminmlarimer sup89supzrpertuzumabpetimagingrevealspaclitaxeltreatmentefficacyispositivelycorrelatedwithher2expressioninhumanbreastcancerxenograftmousemodels AT suzanneelapi sup89supzrpertuzumabpetimagingrevealspaclitaxeltreatmentefficacyispositivelycorrelatedwithher2expressioninhumanbreastcancerxenograftmousemodels AT annagsorace sup89supzrpertuzumabpetimagingrevealspaclitaxeltreatmentefficacyispositivelycorrelatedwithher2expressioninhumanbreastcancerxenograftmousemodels |